(Total Views: 460)
Posted On: 02/22/2021 2:11:20 PM
Post# of 145890
FDA new guidance.
If you look at the specifics of combos they're talking about spike binding MABs so that virus variations are covered, not leronlimab.
If you look at the specifics of combos they're talking about spike binding MABs so that virus variations are covered, not leronlimab.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)